drugset / Trial / NCT06816914
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial
Phase 2
Recruiting
84 enrolled
Taichung Veterans General Hospital
Chang Gung Memorial Hospital · collabChina Medical University Hospital · collabKaohsiung Medical University Chung-Ho Memorial Hospital · collabNational Cheng-Kung University Hospital · collabNational Taiwan University Hospital · collabTaipei Veterans General Hospital, Taiwan · collabTri-Service General Hospital (TSGH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the safety and activity of NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin) in the perioperative and adjuvant treatment in resectable pancreatic adeneocarcinoma.
Timeline
- Start
- 2025-03-05
- Primary completion
- 2027-02-05
- Completion
- 2028-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |